Arcus Biosciences (RCUS) Cash & Current Investments (2017 - 2026)

Arcus Biosciences' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $822.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 17.55% year-over-year to $822.0 million; the TTM figure through Mar 2026 stood at $822.0 million (down 17.55% YoY), while the FY2025 annual figure was $981.0 million, changed 0.31% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $822.0 million, down from $981.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $1.2 billion in Q1 2022, with the low at $759.0 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $978.0 million (2024), against an average of $968.2 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments surged 102.2% in 2022, then retreated 24.78% in 2023.
• Arcus Biosciences' Cash & Current Investments stood at $1.0 billion in 2022, then retreated by 24.78% to $759.0 million in 2023, then increased by 28.85% to $978.0 million in 2024, then climbed by 0.31% to $981.0 million in 2025, then dropped by 16.21% to $822.0 million in 2026.
• Business Quant data shows RCUS's Cash & Current Investments at $822.0 million in Q1 2026, $981.0 million in Q4 2025, and $831.0 million in Q3 2025.